Figure 3.
In vivo efficacy and antitumor immunity elicited after vvdd-tdTomato-mDAI treatment in an immunocompetent syngeneic melanoma model. B16-OVA melanoma tumors were established by injecting 1 × 105 B16-OVA cells subcutaneously into other flank of C57BL/6J mice (N = 12 per group). Established tumors (one tumor per mouse, ~4 × 4 mm in diameter) were injected intratumorally with viruses in volume of 50 μl on day 0 with 3 × 106 pfu/tumor and on day 2 with 1 × 106 pfu/tumor. Mock tumors were injected with phosphate-buffered saline only. (a) Tumor growth was measured over time (day 0 = day when the first virus treatment was given). (b) General CD8+ and CD4+ T-cells and (c) tumor-specific (OVA peptide-specific) CD8+ T-cells were analyzed by flow cytometry from the tumors of treated mice 12 after the first virus treatment.